DrugPatentWatch Database Preview
Ariad Company Profile
What is the competitive landscape for ARIAD, and when can generic versions of ARIAD drugs launch?
ARIAD has two approved drugs.
There are seven US patents protecting ARIAD drugs.
There are one hundred and twenty-one patent family members on ARIAD drugs in thirty-one countries and twenty-three supplementary protection certificates in fifteen countries.
Summary for Ariad
| International Patents: | 121 |
| US Patents: | 7 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
| Patent Litigation for Ariad: | See patent lawsuits for Ariad |
Drugs and US Patents for Ariad
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ariad | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-001 | Dec 14, 2012 | RX | Yes | No | See Pricing | See Pricing | |||||
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-001 | Apr 28, 2017 | RX | Yes | No | 10,385,078 | See Pricing | Y | Y | See Pricing | ||
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-003 | Oct 2, 2017 | RX | Yes | Yes | 9,611,283 | See Pricing | See Pricing | ||||
| Ariad | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-002 | Dec 14, 2012 | RX | Yes | Yes | 9,029,533 | See Pricing | See Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Ariad Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 343042 | See Pricing |
| Spain | 2645689 | See Pricing |
| Chile | 2017000979 | See Pricing |
| China | 103044432 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ariad Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1973545 | PA2013027 | Lithuania | See Pricing | PRODUCT NAME: PONATINIBUM; REGISTRATION NO/DATE: EU/1/13/839/001, 2013 07 01 EU/1/13/839/002, 2013 07 01 EU/1/13/839/003, 2013 07 01 EU/1/13/839/004 20130701 |
| 1973545 | 490 | Finland | See Pricing | |
| 1973545 | 2013C/073 | Belgium | See Pricing | PRODUCT NAME: PONATINIB; AUTHORISATION NUMBER AND DATE: EU/1/13/839/001 20130703 |
| 2300013 | CA 2019 00028 | Denmark | See Pricing | PRODUCT NAME: BRIGATINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT HERAF; REG. NO/DATE: EU/1/18/1264 20181126 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
